VIIa - Latest Advances

Real World Experience with use of Coagulation Factor VIIa at an Academic Medical Center.

Journal: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Published: December 11, 2025

Genetics of prelingual isolated deafness and Usher syndrome in the Maghreb and Jordan: Harnessing the potential of homozygosity.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: December 08, 2025

The Factor Approach: Coagulation Treatment Optimization and Recommendations (FACTOR).

Journal: Journal of the advanced practitioner in oncology

Published: December 05, 2025

Recombinant Factor VIIa Prophylaxis in 2 Brothers with Bernard-Soulier Syndrome.

Journal: The American journal of case reports

Published: November 19, 2025

Analysis of pathogenic variant carriage for MYO7A, PCDH15, and CDH23 genes among newborns based on high-throughput sequencing technique

Journal: Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics

Published: November 13, 2025

Epidemiological and genetic insights of Usher syndrome in Turkish population: A cross-sectional preliminary study from University of Health Sciences, Turkey.

Journal: The Journal of international medical research

Published: November 07, 2025

Donor and Acceptor Characteristics of Group IV and VII Doped BiNbO4: A Hybrid Density Functional Investigation.

Journal: Langmuir : the ACS journal of surfaces and colloids

Published: September 18, 2025

Antithrombin-binding heparan sulfate is ubiquitously expressed in epithelial cells and suppresses pancreatic tumorigenesis.

Journal: The Journal of clinical investigation

Published: September 09, 2025

Identification of microRNA-Related Target Genes for the Development of Otic Organoids.

Journal: International journal of molecular sciences

Published: September 03, 2025

Use of Nebulized Tranexamic acid (TA) in combination with nebulized recombinant coagulation factor VIIa to treat hemoptysis in pediatric patients with cancer at end-of-life (EOL).

Journal: Journal of pain and symptom management

Published: August 18, 2025

Recombinant Factor VIIa Versus Prothrombin Complex Concentrate in Patients Undergoing Cardiac Surgery: A Systematic Review and Meta-analysis.

Journal: Journal of cardiothoracic and vascular anesthesia

Published: August 11, 2025

Characterization of thromboembolic events after recombinant coagulation factor VIIa (rFVIIa - NovoSeven®) use in cardiac surgery: A descriptive pilot study.

Journal: Annales pharmaceutiques francaises

Published: August 07, 2025

Filters

Real World Experience with use of Coagulation Factor VIIa at an Academic Medical Center.

Real World Experience with use of Coagulation Factor VIIa at an Academic Medical Center.

Genetics of prelingual isolated deafness and Usher syndrome in the Maghreb and Jordan: Harnessing the potential of homozygosity.

Genetics of prelingual isolated deafness and Usher syndrome in the Maghreb and Jordan: Harnessing the potential of homozygosity.

The Factor Approach: Coagulation Treatment Optimization and Recommendations (FACTOR).

The Factor Approach: Coagulation Treatment Optimization and Recommendations (FACTOR).

Recombinant Factor VIIa Prophylaxis in 2 Brothers with Bernard-Soulier Syndrome.

Recombinant Factor VIIa Prophylaxis in 2 Brothers with Bernard-Soulier Syndrome.

Analysis of pathogenic variant carriage for MYO7A, PCDH15, and CDH23 genes among newborns based on high-throughput sequencing technique

Analysis of pathogenic variant carriage for MYO7A, PCDH15, and CDH23 genes among newborns based on high-throughput sequencing technique

Epidemiological and genetic insights of Usher syndrome in Turkish population: A cross-sectional preliminary study from University of Health Sciences, Turkey.

Epidemiological and genetic insights of Usher syndrome in Turkish population: A cross-sectional preliminary study from University of Health Sciences, Turkey.

Donor and Acceptor Characteristics of Group IV and VII Doped BiNbO4: A Hybrid Density Functional Investigation.

Donor and Acceptor Characteristics of Group IV and VII Doped BiNbO4: A Hybrid Density Functional Investigation.

Antithrombin-binding heparan sulfate is ubiquitously expressed in epithelial cells and suppresses pancreatic tumorigenesis.

Antithrombin-binding heparan sulfate is ubiquitously expressed in epithelial cells and suppresses pancreatic tumorigenesis.

Identification of microRNA-Related Target Genes for the Development of Otic Organoids.

Identification of microRNA-Related Target Genes for the Development of Otic Organoids.

Use of Nebulized Tranexamic acid (TA) in combination with nebulized recombinant coagulation factor VIIa to treat hemoptysis in pediatric patients with cancer at end-of-life (EOL).

Use of Nebulized Tranexamic acid (TA) in combination with nebulized recombinant coagulation factor VIIa to treat hemoptysis in pediatric patients with cancer at end-of-life (EOL).

Recombinant Factor VIIa Versus Prothrombin Complex Concentrate in Patients Undergoing Cardiac Surgery: A Systematic Review and Meta-analysis.

Recombinant Factor VIIa Versus Prothrombin Complex Concentrate in Patients Undergoing Cardiac Surgery: A Systematic Review and Meta-analysis.

Characterization of thromboembolic events after recombinant coagulation factor VIIa (rFVIIa - NovoSeven®) use in cardiac surgery: A descriptive pilot study.

Characterization of thromboembolic events after recombinant coagulation factor VIIa (rFVIIa - NovoSeven®) use in cardiac surgery: A descriptive pilot study.